Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults

NCT02536183 is registered in ClinicalTrials.gov with AeRang Kim as lead sponsor.

NCT NCT02536183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02536183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults
Lead sponsor
AeRang Kim
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2016
Completion date
October 31, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, germ cell tumors, hepatic tumor, neuroblastoma, osteosarcoma, pediatric cancer, rhabdomyosarcoma, soft tissue sarcomas, solid tumors, wilms tumor